Drug Profile

ES 008

Alternative Names: ES-008; ES008-a

Latest Information Update: 07 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Elpiscience Biopharmaceuticals
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Leukocyte immunoglobulin-like receptor B1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

05 Nov 2023 Pharmacodynamics data from preclinical studies in Cancer released by Elpiscience Biopharmaceuticals
31 Jul 2021 Preclinical trials in Cancer in China (Parenteral) (Elpiscience pipeline, July 2021)
28 Sep 2020 Elpiscience Biopharmaceuticals plans CMC evaluations in Cancer, between 2021 and 2023 (Elpiscience Biopharmaceuticals pipeline, September 2020).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com